To launch the project, two workgroups were established – the Drafting Workgroup and the Multi-Stakeholder Alignment Workgroup (MSAW). The Drafting Workgroup consisted of seven patient advocates, two legal experts, a PFMD representative and three representatives from pharmaceutical companies.
The MSAW represents all RAPP project partners with legal expertise from patient advocacy and pharmaceutical companies. Both workgroups provided multiple cycles of review and feedback throughout the project and ideas and advice on all documents drafted. Legal experts from the following companies were involved: Bayer, Bristol-Myers Squibb, Celgene, Janssen, Merck MSD, Novartis, Novo Nordisk, Pfizer, Roche, Servier, Takeda.